In major news released today, Human Longevity, Inc. (HLI) announced that is is acquiring LifebankUSA, a cord blood, placental blood, and tissue bank owned by Celgene Cellular Therapeutics.
Based in San Diego, CA, Human Longevity, Inc. is an innovative company that specializes in the use of whole genome sequence analysis, clinical imaging, and machine learning to extend health across a longer human lifespan. LifebankUSA, based in Cedar Knolls, NJ, is the “the only company that offers cord blood, placenta blood and tissue banking – and the first to release placenta-derived stem cells for a successful transplant.” Celgene Cellular Therapeutics (CCT), the parent company of LifeBankUSA, specializes in cell therapy and regenerative medicine products, using LifeBankUSA to source its cell therapy, organ and tissue products, several of which are now being explored in clinical trials (PDA001, PDA002, and others).
The move will position Human Longevity, Inc. to offers its newborn genome sequencing product in combination to its newly acquired stem cell banking services.
[Read more…]